Japanese drug firm Astellas seeks Dx companions with 'precision medicine' strategy
This article was originally published in Clinica
Executive Summary
By focusing its latest "R&D day" solely on oncology, Japanese drug company Astellas intended to send out a clear message that it is serious about building its presence in the field, outlining an expanding development pipeline that is particularly well stocked at the Phase I/II stage.